Connection
Heather Moore to Class I Phosphatidylinositol 3-Kinases
This is a "connection" page, showing publications Heather Moore has written about Class I Phosphatidylinositol 3-Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.042 |
|
|
|
-
Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Res Treat. 2019 Nov; 178(1):121-133.
Score: 0.042